Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1668018

	registered interest
	date	07/11/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Abiraterone
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will review the decision to reject the use of the drug Abiraterone to tackle prostate cancer.
	tabling member constituency	Richmond Park
	tabling member printed	Sarah Olney
	uin	377
	answer	answer is ministerial correction date of answer 09/11/2023 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body that guides the National Health Service on funding new medicines, based on clinical and cost-effectiveness.. The NHS is legally required to fund medicines recommended by NICE, usually within 3 months of final guidance.</p><p>NICE has recommended abiraterone for the treatment of metastatic hormone-relapsed prostate cancer before chemotherapy is indicated and for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen. NHS England funds abiraterone in line with NICE’s recommendations, ensuring access for eligible patients.</p><p>Abiraterone is not licensed for the treatment of non-metastatic prostate cancer and has therefore not been appraised by NICE for such use. NHS England is currently considering a clinical policy proposal for abiraterone as a treatment option for potential use in specific cases. The proposal is due to be discussed later this month, with potential stakeholder testing by January 2024, if supported.</p> answering member constituency Colchester answering member printed Will Quince question first answered 09/11/2023 11:00:41 answering member 4423 label Biography information for Will Quince
	tabling member	4591 label Biography information for Sarah Olney

1666622

	registered interest
	date	23/10/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Attention Deficit Hyperactivity Disorder: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help ensure an adequate supply of (a) methylphenidate, (b) lisdexamfetamine and (c) guanfacine.
	tabling member constituency	Richmond Park
	tabling member printed	Sarah Olney
	uin	203897
	answer	answer is ministerial correction date of answer 26/10/2023 answer text <p>We are aware of disruptions to the supply of medicines used for the management of attention deficit hyperactivity disorder (ADHD), including methylphenidate, lisdexamfetamine and guanfacine. Some issues have now been resolved. However, we know that there are currently disruptions to the supply of some other medicines, primarily driven by issues which have resulted in capacity constraints at key manufacturing sites. These issues are expected to resolve by the end of December 2023.</p><p>We understand how frustrating and distressing medicine shortages can be and we want to assure patients that we are working intensively with the respective manufacturers to resolve the issues as soon as possible and to ensure patients have continuous access to ADHD medicines in the United Kingdom, in the short and long term.</p><p>We have issued communications to the National Health Service to advise healthcare professionals on management of patients whilst there continue to be disruptions to supplies. Patients are advised to speak to their clinician regarding any concerns they have and to discuss the suitability of treatment with alternative medicines.</p> answering member constituency Colchester answering member printed Will Quince question first answered 26/10/2023 08:58:43 answering member 4423 label Biography information for Will Quince
	tabling member	4591 label Biography information for Sarah Olney

1642151

	registered interest
	date	06/06/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Haemochromatosis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that patients' level of access to testing for genetic haemochromatosis is consistent with the criteria set out in the NHS Genomics Test Directory.
	tabling member constituency	Richmond Park
	tabling member printed	Sarah Olney
	uin	188083
	answer	answer is ministerial correction date of answer 13/06/2023 answer text <p>Genomic testing in the National Health Service in England is provided through the NHS Genomic Medicine Service (GMS) and delivered by a national genomic testing network of seven NHS Genomic Laboratory Hubs (GLHs). The NHS GLHs deliver testing as directed by the National Genomic Test Directory, which outlines the full range of genomic testing offered by the NHS and sets out the eligibility criteria for patients to access testing as well as the genomic targets to be tested and the method that should be used, it is applicable nationally, providing a standardised approach.</p><p>The performance of the GLHs is monitored quarterly through an assurance framework, which ensures all GLHs are operating to national quality standards and identifies and minimises any potential variation, ensuring consistent delivery of the criteria outlined in the National Genomic Test Directory.</p> answering member constituency Colchester answering member printed Will Quince question first answered 13/06/2023 11:46:29 answering member 4423 label Biography information for Will Quince previous answer version 80606 answering member constituency Colchester answering member printed Will Quince answering member 4423 label Biography information for Will Quince
	tabling member	4591 label Biography information for Sarah Olney

1642152

	registered interest
	date	06/06/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Haemochromatosis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what funding his Department provides to GP practices for genetic testing for genetic haemochromatosis.
	tabling member constituency	Richmond Park
	tabling member printed	Sarah Olney
	uin	188084
	answer	answer is ministerial correction date of answer 13/06/2023 answer text <p>Whilst general practitioner (GP) practices are not directly funded to provide genomic testing for haemochromatosis, testing is available for all eligible patients across England through an NHS England centrally funded service. Any patient who is suspected of having haemochromatosis can be referred for testing via their local NHS Clinical Genomic Services (NHS CGSs), a comprehensive clinical genomic and counselling service that directs the diagnosis, risk assessment and lifelong clinical management of patients and their families who have, or are at risk of having, a rare genetic condition.</p><p>Individuals should discuss with their healthcare professional, for example, their GP, whether genomic testing is appropriate for them. Their GP will then make a decision whether to refer the individual either directly or via a NHS CGS for genomic testing following clinical review and the relevant genomic testing eligibility criteria.</p> answering member constituency Colchester answering member printed Will Quince question first answered 13/06/2023 12:08:18 answering member 4423 label Biography information for Will Quince previous answer version 80607 answering member constituency Colchester answering member printed Will Quince answering member 4423 label Biography information for Will Quince
	tabling member	4591 label Biography information for Sarah Olney

1640139

	registered interest
	date	24/05/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Mental Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will make it his policy to continue to fund the NHS staff mental health and wellbeing hubs beyond 2022/23.
	tabling member constituency	Richmond Park
	tabling member printed	Sarah Olney
	uin	186792
	answer	answer is ministerial correction date of answer 05/06/2023 answer text <p>Staff mental health hubs were established in October 2020 with funding subsequently extended to March 2023. They were funded on a non-recurrent basis using additional funding from Government as a short-term response to the pressure on the workforce from COVID-19. A number of systems across the National Health Service have chosen to continue to fund the work of the hubs. We are working with NHS England to explore how we can ensure all staff can access specialist support when they need it.</p><p>The health and wellbeing of NHS staff is a priority. NHS England has developed a range of health and wellbeing support for staff and earlier this year published a strategy to grow and strengthen occupational health and wellbeing services across the NHS. NHS staff can continue to access NHS Practitioner Health, a national support service for staff with more complex mental health needs brough about by serious issues such as trauma or addiction.</p> answering member constituency Colchester answering member printed Will Quince question first answered 05/06/2023 15:44:05 answering member 4423 label Biography information for Will Quince
	tabling member	4591 label Biography information for Sarah Olney

1612441

	registered interest
	date	19/04/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Palantir: Databases
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 17 April to Question 175561 on Palantir: Databases, for what reason that Answer did not mention the common law duty of confidentiality.
	tabling member constituency	Richmond Park
	tabling member printed	Sarah Olney
	uin	181731
	answer	answer is ministerial correction date of answer 26/04/2023 answer text <p>Question 175561 asked about the security of data, therefore, the answer summarised the key legislation and standards to which the Foundry platform conforms. It was not felt necessary to spell out common laws which apply to everyone in the United Kingdom. The common law duty of confidentiality is that the use or disclosure of personal information held in confidence can only happen when there is a lawful basis, or consent has been given, or where there is overriding public interest in the disclosure. The data which the platform collates is data which NHS England has a lawful basis for collecting for its statutory purposes. It cannot be used or disclosed for other purposes, and Palantir do not have access to the data. Therefore, the common law duty of confidentiality is fully respected.</p> answering member constituency Colchester answering member printed Will Quince question first answered 26/04/2023 16:23:54 answering member 4423 label Biography information for Will Quince previous answer version 70732 answering member constituency Colchester answering member printed Will Quince answering member 4423 label Biography information for Will Quince
	tabling member	4591 label Biography information for Sarah Olney

1608200

	registered interest
	date	28/03/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Palantir: Databases
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the security of NHS data held by Palantir Technologies.
	tabling member constituency	Richmond Park
	tabling member printed	Sarah Olney
	uin	175561
	answer	answer is ministerial correction date of answer 17/04/2023 answer text <p>Data processes and systems within the Palantir Foundry software platform are required to comply with the Technology Code of Practice, Government Digital Services standards, the Department’s Guide to good practice for digital and data-driven health technologies, the Data Protection Act 2018 and the United Kingdom's implementation of the General Data Protection Regulation, Information Commissioner’s Office guidance and associated regulations, standards and guidance.</p> answering member constituency Colchester answering member printed Will Quince question first answered 17/04/2023 13:41:54 answering member 4423 label Biography information for Will Quince
	tabling member	4591 label Biography information for Sarah Olney

1608376

	registered interest
	date	28/03/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health Services: Standards
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, which consultations published by their Department are awaiting a response; and when each of those responses (a) were initially planned to and (b) will be published.
	tabling member constituency	Richmond Park
	tabling member printed	Sarah Olney
	uin	175639
	answer	answer is ministerial correction date of answer 13/04/2023 answer text <p>Policy teams across the Department consult regularly during the policy development and implementation cycle. Information is available on GOV.UK about all open and closed consultations published by the Department, including the closing date for open consultations and, where available, the Government's response. The Cabinet Office has published best practice ‘consultation principles’ for Government departments.</p> answering member constituency Colchester answering member printed Will Quince question first answered 13/04/2023 10:23:33 answering member 4423 label Biography information for Will Quince
	tabling member	4591 label Biography information for Sarah Olney

1600484

	registered interest
	date	01/03/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Surgery: Private Sector
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 1 March 2023 to Question 147198 on Surgery: Private Sector, what the total cost to the public purse was of the 1,891,632 NHS-funded procedures carried out by non-NHS providers in the financial year 2021-22.
	tabling member constituency	Richmond Park
	tabling member printed	Sarah Olney
	uin	156210
	answer	answer is ministerial correction date of answer 06/03/2023 answer text <p>This information is not collected in the format requested. Data on the procedures performed by non National Health Service providers and the associated cost is not held by the department.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 156211 question first answered 06/03/2023 15:26:10 answering member 4423 label Biography information for Will Quince
	tabling member	4591 label Biography information for Sarah Olney

1600490

	registered interest
	date	01/03/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Surgery: Private Sector
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 1 March 2023 to Question 147198 on Surgery: Private Sector, if he will provide a regional breakdown of NHS funded procedures carried out by non-NHS providers in 2021-22.
	tabling member constituency	Richmond Park
	tabling member printed	Sarah Olney
	uin	156211
	answer	answer is ministerial correction date of answer 06/03/2023 answer text <p>This information is not collected in the format requested. Data on the procedures performed by non National Health Service providers and the associated cost is not held by the department.</p> answering member constituency Colchester answering member printed Will Quince grouped question UIN 156210 question first answered 06/03/2023 15:26:10 answering member 4423 label Biography information for Will Quince
	tabling member	4591 label Biography information for Sarah Olney